Plain-English translation of NCT04063540 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication usually used to treat high blood pressure, might help prevent migraine auras — the visual or sensory warnings that come before some migraines. Researchers believe this medication may work by blocking certain channels in the brain that are involved in migraines. The study will compare how often migraines occur when people take this medication versus when they take a placebo (a dummy pill with no active ingredient).
Scientists have discovered that certain ion channels in the brain may play a role in how migraines with aura develop. This medication blocks those channels in animal studies, suggesting it could help prevent migraines in people. This trial will test whether this approach actually works in patients who suffer from frequent migraines with aura.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo for 12 weeks, then stop for a 4-week break, and then take the opposite treatment (placebo or medication) for another 12 weeks. This crossover design helps researchers see how well the medication works compared to placebo in the same person. You'll visit one of three French headache centers, keep track of your migraines, and have your blood checked to make sure the medication is safe for you.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
France